Navigation Links
JDRF clinical panel recommends next steps for artificial pancreas clinical testing
Date:11/10/2010

e the regulatory pathway so final studies can be completed and better technologies can be made available to adults and children struggling with this difficult disease," added Mr. Brewer.

About JDRF's Artificial Pancreas Project

JDRF launched the Artificial Pancreas Project in 2005 to speed the development of automated diabetes management systems. A self-regulating system, the artificial pancreas would be able to sense sugar levels continuously and automatically release the right amount of insulin at the right times eliminating the need for multiple blood tests, insulin injections and therefore lifting the daily burden associated with managing diabetes.

Since that time, JDRF has supported a number of initiatives that have advanced progress toward the development of an artificial pancreas. This has included the formation of the Artificial Pancreas Consortium, a group of university-based mathematicians, engineers, and diabetes experts to develop the computer algorithms that are needed to connect the devices needed to form a closed-loop system.

In addition to the consortium, JDRF has collaborated with several industry partners to develop a first-generation artificial pancreas system, as well as better and faster-acting insulin products, a key component of developing a safe and effective artificial pancreas system.


'/>"/>

Contact: Joana Casas
mcasas@jdrf.org
212-479-7560
Juvenile Diabetes Research Foundation International
Source:Eurekalert

Page: 1 2 3

Related biology news :

1. A new journal where molecular biology meets clinical research
2. Self-assembling nano-fiber gel delivers high concentrations of clinically approved drugs
3. Biochemistry of human physiology in health and disease is focus of updated clinical text
4. New book helps medical students master clinical skills
5. In just 5 years, gene discovery to clinical trial of potential treatment
6. Far-reaching genetics topics to be addressed: 2009 Annual Clinical Genetics Meeting, March 25-29
7. Genome Medicine: Bridging the gap between research and clinical practice
8. 3 new informatics pilot projects to aid clinical and translational scientists nationwide
9. TGen Clinical Research Services at Scottsdale Healthcare and Mayo Clinic study new cancer drug
10. ABC publishes monograph on scientific and clinical research of Sinupret
11. Researchers win award for best clinical paper in orthopedic physical therapy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2014)... Eight of the top 10 U.S. cities that have ... public inconveniences as frequent road closures, overwhelmed storm drains ... a new NOAA technical report. , This nuisance flooding, ... three U.S. coasts, between 300 and 925 percent since ... Nuisance Flood Frequency Changes around the United States, also ...
(Date:7/28/2014)... study suggest two ways to effectively address the problem that ... women, compared to women of a normal body mass index. ... but as the population has increased in weight, concern has ... Studies have consistently found that obesity has a negative impact ... affect how well the pill prevents pregnancy. , ...
(Date:7/28/2014)... He calls himself the bug hunter, but the ... only be found and identified with special methods and ... Kansas State Veterinary Diagnostic Laboratory at Kansas State University, ... porcine enterovirus G, which is an important find in ... in cells, but didn,t know what it was," Hause ...
Breaking Biology News(10 mins):NOAA: 'Nuisance flooding' an increasing problem as coastal sea levels rise 2NOAA: 'Nuisance flooding' an increasing problem as coastal sea levels rise 3Strategies identified to improve oral contraceptive success with obese women 2Researcher using next-generation sequencing to rapidly identify pathogens 2Researcher using next-generation sequencing to rapidly identify pathogens 3
... Junrong Zheng,s techniques to see the fine details of how ... highly prestigious Packard Fellowship. Zheng and his team ... grant that comes with the fellowship to build a laser-based ... and orientation -- of any molecule, no matter how complex. ...
... BOSTON, MA (October 20, 2011) Results from a ... copper surfaces in intensive care unit rooms reduced the amount ... in a 41 percent reduction in the hospital acquired infection ... first to demonstrate the value of a passive infection control ...
... of Bristol has been awarded 1.3 million to unlock the ... to produce silica the fundamental constituent of glass. It ... the next generation of medical imaging tools. Inspired by ... Paul Curnow from the University,s School of Biochemistry has been ...
Cached Biology News:Rice's Zheng wins Packard Fellowship 2Study proves new technology kills bacteria 2
(Date:7/28/2014)... Calif. , July 28, 2014  InterMune, Inc. ... will release its second quarter 2014 financial results at ... 6, 2014. A live conference call and webcast will be ... same day. Interested investors and others may ... or +1 212-231-2900 (international), conference ID#21728775. A replay of the ...
(Date:7/25/2014)... 2014 "Ischemic Stroke and Cerebral ... data on the Ischemic Stroke and Cerebral Stroke ... and data relating to the clinical trials on ... global Ischemic Stroke Research Report 2014 at: ... the trial numbers and their recruitment status as ...
(Date:7/25/2014)... New York (PRWEB) July 25, 2014 ... Market Research, "Biological Drugs Market - Global Industry Analysis, ... the global biological drugs market is estimated at USD ... at a CAGR of 10.1% from 2014 to 2020, ... in 2020. , The biological drugs market is witnessing ...
(Date:7/25/2014)... July 25, 2014 /PRNewswire-iReach/ -- Xybion Corporation, the ... global corporations operating in highly regulated industries, announced ... annual Global User Group Conference, Xybion International Exchange, ... Philadelphia, Pennsylvania at the Sheraton Society ... This year,s conference theme ...
Breaking Biology Technology:InterMune to Release Second Quarter Financial Results on August 6 2Ischemic Stroke and Cerebral Stroke Global Clinical Trials Review H2, 2014: MarketResearchReports.Biz 2Ischemic Stroke and Cerebral Stroke Global Clinical Trials Review H2, 2014: MarketResearchReports.Biz 3Biological Drugs Market: Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2020 2Biological Drugs Market: Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2020 3Xybion Announces It Will Host International User Conference in Philadelphia 2Xybion Announces It Will Host International User Conference in Philadelphia 3
... Productivity. , ... Grand Forks, ND (Vocus) December 10, ... individual management practices and fields will become increasingly important to growers, ... Research and Development, will tell agricultural leaders today at the ...
... Dosing Regimen , , ... long-acting therapy (LAT) demonstrated statistically significant symptom control compared ... study presented today (1). Statistical significance was evidenced ... equivalent [eq.a]), when given every 4 weeks with a ...
... Journal Blood for the American Society of Hematology Annual Meeting ... 10 Alfacell Corporation (Nasdaq: ACEL ) today ... in Blood (2008 112: Abstract 4205 & 2008 ... show anti-tumor activity in chronic lymphocytic leukemia (CLL) and acute ...
Cached Biology Technology:Matching Genetics, Technology and Management Practices Critical to Meeting Strong Demand for Agricultural Crops 2Matching Genetics, Technology and Management Practices Critical to Meeting Strong Demand for Agricultural Crops 3Matching Genetics, Technology and Management Practices Critical to Meeting Strong Demand for Agricultural Crops 4Phase 3 Data Demonstrate Efficacy and Tolerability of Paliperidone Palmitate, an Investigational Long-Acting Therapy for the Treatment of Schizophrenia 2Phase 3 Data Demonstrate Efficacy and Tolerability of Paliperidone Palmitate, an Investigational Long-Acting Therapy for the Treatment of Schizophrenia 3Phase 3 Data Demonstrate Efficacy and Tolerability of Paliperidone Palmitate, an Investigational Long-Acting Therapy for the Treatment of Schizophrenia 4Phase 3 Data Demonstrate Efficacy and Tolerability of Paliperidone Palmitate, an Investigational Long-Acting Therapy for the Treatment of Schizophrenia 5Phase 3 Data Demonstrate Efficacy and Tolerability of Paliperidone Palmitate, an Investigational Long-Acting Therapy for the Treatment of Schizophrenia 6Phase 3 Data Demonstrate Efficacy and Tolerability of Paliperidone Palmitate, an Investigational Long-Acting Therapy for the Treatment of Schizophrenia 7Phase 3 Data Demonstrate Efficacy and Tolerability of Paliperidone Palmitate, an Investigational Long-Acting Therapy for the Treatment of Schizophrenia 8Phase 3 Data Demonstrate Efficacy and Tolerability of Paliperidone Palmitate, an Investigational Long-Acting Therapy for the Treatment of Schizophrenia 9Alfacell's ONCONASE(R) and R-Amphinase Show Anti-Tumor Activity in Chronic Lymphocytic Leukemia and Acute Myeloblastic Leukemia Cells 2Alfacell's ONCONASE(R) and R-Amphinase Show Anti-Tumor Activity in Chronic Lymphocytic Leukemia and Acute Myeloblastic Leukemia Cells 3Alfacell's ONCONASE(R) and R-Amphinase Show Anti-Tumor Activity in Chronic Lymphocytic Leukemia and Acute Myeloblastic Leukemia Cells 4Alfacell's ONCONASE(R) and R-Amphinase Show Anti-Tumor Activity in Chronic Lymphocytic Leukemia and Acute Myeloblastic Leukemia Cells 5
Rabbit polyclonal to Lck (phospho Y192) ( Abpromise for all tested applications). entrezGeneID: 3932 SwissProtID: P06239...
...
Rabbit polyclonal to LCAT ( Abpromise for all tested applications). entrezGeneID: 3931 SwissProtID: P04180...
HAMP Immunogen: HAMP (AAH20612, 25 a.a. ~ 85 a.a) full length recombinant protein with GST tag. Storage: -20 C, Avoid Freeze/Thaw Cycles *Available for distribution in the US only...
Biology Products: